- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies for Dodging the Obstacles in CAR T Cell Therapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-01
DOI
10.3389/fonc.2021.627549
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FDA approves fourth CAR-T cell therapy
- (2021) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy
- (2020) Greta Giordano-Attianese et al. NATURE BIOTECHNOLOGY
- Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma
- (2020) Dongrui Wang et al. Science Translational Medicine
- Lessons from the A2A Adenosine Receptor Antagonist–Enabled Tumor Regression and Survival in Patients with Treatment-Refractory Renal Cell Cancer
- (2020) Michail V. Sitkovsky Cancer Discovery
- Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability
- (2020) Sonia Guedan et al. JOURNAL OF CLINICAL INVESTIGATION
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery
- (2020) Cesar Sommer et al. MOLECULAR THERAPY
- Engineered off-the-shelf therapeutic T cells resist host immune rejection
- (2020) Feiyan Mo et al. NATURE BIOTECHNOLOGY
- PET reporter gene imaging and ganciclovir-mediated ablation of chimeric antigen receptor T-cells in solid tumors
- (2020) Surya Murty et al. CANCER RESEARCH
- Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
- (2020) Kevin R. Parker et al. CELL
- Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy
- (2020) Katarina Halpin-Veszeleiova et al. CURRENT OPINION IN PHARMACOLOGY
- Preventing Ubiquitination Improves CAR T Cell Therapy via ‘CAR Merry-Go-Around’
- (2020) Nicole M. Chapman et al. IMMUNITY
- CAR-T Therapy Is Approved for Mantle Cell Lymphoma
- (2020) Rebecca Voelker JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia
- (2020) Mohadese Hashem Boroojerdi et al. MEDICAL ONCOLOGY
- T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication
- (2020) Yu-Yang Ng et al. MOLECULAR THERAPY
- ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies
- (2020) Jingyu Chen et al. Frontiers in Oncology
- T cell stemness and dysfunction in tumors are triggered by a common mechanism
- (2019) Suman Kumar Vodnala et al. SCIENCE
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
- (2019) Matthew R. Collinson-Pautz et al. LEUKEMIA
- Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-Cells prevents monocyte-dependent release of key cytokine release syndrome mediators
- (2019) Mohit Sachdeva et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells
- (2019) Esther Drent et al. CLINICAL CANCER RESEARCH
- Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
- (2019) Yushu Joy Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
- (2019) Stefan Stoiber et al. Cells
- Modulation of chimeric antigen receptor surface expression by a small molecule switch
- (2019) Alexandre Juillerat et al. BMC BIOTECHNOLOGY
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy
- (2019) Joshua A. Hill et al. BLOOD REVIEWS
- The potential role of γδ T cells after allogeneic HCT for leukemia
- (2018) Rupert Handgretinger et al. BLOOD
- Nanobody Based Dual Specific CARs
- (2018) Stijn De Munter et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
- (2018) Ashley V. Menk et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
- (2018) Anna Capsomidis et al. MOLECULAR THERAPY
- Long Terminal Repeat CRISPR-CAR-Coupled “Universal” T Cells Mediate Potent Anti-leukemic Effects
- (2018) Christos Georgiadis et al. MOLECULAR THERAPY
- Rewiring T-cell responses to soluble factors with chimeric antigen receptors
- (2018) ZeNan L Chang et al. Nature Chemical Biology
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects
- (2018) Yuki Kagoya et al. NATURE MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
- (2018) André Veillette et al. TRENDS IN IMMUNOLOGY
- Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy
- (2018) Jonathan Fisher et al. Frontiers in Immunology
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
- (2018) Rosalie M. Sterner et al. BLOOD
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- Teaching an old dog new tricks: next-generation CAR T cells
- (2018) Nicholas Tokarew et al. BRITISH JOURNAL OF CANCER
- FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma
- (2018) Najat Bouchkouj et al. CLINICAL CANCER RESEARCH
- Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
- (2018) Verena Staedtke et al. NATURE
- CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies
- (2017) Alexandra Martyniszyn et al. HUMAN GENE THERAPY
- Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
- (2017) Daniel T. MacLeod et al. MOLECULAR THERAPY
- Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor
- (2017) Jonathan Fisher et al. MOLECULAR THERAPY
- Masked Chimeric Antigen Receptor for Tumor-Specific Activation
- (2017) Xiaolu Han et al. MOLECULAR THERAPY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Immunotherapy: Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers
- (2017) Vinay Prasad Nature Reviews Clinical Oncology
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- A versatile system for rapid multiplex genome-edited CAR T cell generation
- (2017) Jiangtao Ren et al. Oncotarget
- An oxygen sensitive self-decision making engineered CAR T-cell
- (2017) Alexandre Juillerat et al. Scientific Reports
- FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
- (2017) Sara Caratelli et al. Frontiers in Immunology
- A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform
- (2017) Susann Albert et al. OncoImmunology
- Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment
- (2017) Irene Scarfò et al. Journal for ImmunoTherapy of Cancer
- Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer
- (2016) Yu Cao et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
- (2016) Arabella Young et al. CANCER CELL
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
- (2016) Roger Geiger et al. CELL
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
- (2016) Nicole E. Scharping et al. IMMUNITY
- Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
- (2016) Paulina J. Paszkiewicz et al. JOURNAL OF CLINICAL INVESTIGATION
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia
- (2016) Peter J. Siska et al. JOURNAL OF IMMUNOLOGY
- Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
- (2016) Wei Yang et al. NATURE
- Ionic immune suppression within the tumour microenvironment limits T cell effector function
- (2016) Robert Eil et al. NATURE
- Receptor combinations hone T-cell therapy
- (2016) Thomas Blankenstein NATURE BIOTECHNOLOGY
- T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
- (2016) E. Zah et al. Cancer Immunology Research
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- Depletion of T Cell Epitopes in Lysostaphin Mitigates Anti-Drug Antibody Response and Enhances Antibacterial Efficacy In Vivo
- (2015) Hongliang Zhao et al. CHEMISTRY & BIOLOGY
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
- (2015) Julien Valton et al. MOLECULAR THERAPY
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Immunological mechanisms of the antitumor effects of supplemental oxygenation
- (2015) Stephen M. Hatfield et al. Science Translational Medicine
- Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
- (2015) E. Wang et al. Cancer Immunology Research
- Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells
- (2015) Jonathan P H Fisher et al. OncoImmunology
- Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors
- (2015) Hannah Karlsson et al. PLoS One
- Neuroblastoma Killing Properties of V 2 and V 2-Negative T Cells Following Expansion by Artificial Antigen-Presenting Cells
- (2014) J. P. H. Fisher et al. CLINICAL CANCER RESEARCH
- The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases
- (2014) Remo C Russo et al. Expert Review of Clinical Immunology
- Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection
- (2014) Stephen M. Hatfield et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Improving the safety of cell therapy products by suicide gene transfer
- (2014) Benjamin S. Jones et al. Frontiers in Pharmacology
- Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
- (2013) H. Torikai et al. BLOOD
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
- (2013) Meenakshi Hegde et al. MOLECULAR THERAPY
- Double or nothing on cancer immunotherapy
- (2013) Ken-ichi Hanada et al. NATURE BIOTECHNOLOGY
- Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
- (2013) L. R. Desnoyers et al. Science Translational Medicine
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease
- (2013) Nobuhide Ueki et al. Nature Communications
- Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo
- (2013) E. Lanitis et al. Cancer Immunology Research
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
- (2013) Zakaria Grada et al. Molecular Therapy-Nucleic Acids
- A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR
- (2012) H. Torikai et al. BLOOD
- Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside
- (2012) Mounia S. Braza et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy
- (2012) YAN-JUN ZHONG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling
- (2012) Scott Wilkie et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Synthesis and Biological Characterization of Protease-Activated Prodrugs of Doxazolidine
- (2012) Benjamin L. Barthel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells
- (2012) Virna Marin et al. Human Gene Therapy Methods
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
- (2011) X. Wang et al. BLOOD
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
- (2011) S. Amarnath et al. Science Translational Medicine
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- An Improved Bicistronic CD20/tCD34 Vector for Efficient Purification and In Vivo Depletion of Gene-Modified T Cells for Adoptive Immunotherapy
- (2010) Isabel Vogler et al. MOLECULAR THERAPY
- A Novel Antitumor Prodrug Platform Designed to Be Cleaved by the Endoprotease Legumain
- (2009) Liron Stern et al. BIOCONJUGATE CHEMISTRY
- Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy
- (2009) M. Griffioen et al. HAEMATOLOGICA
- Monocyte Chemoattractant Protein-1 (MCP-1): An Overview
- (2009) Satish L. Deshmane et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study
- (2009) Fabio Ciceri et al. LANCET ONCOLOGY
- Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication
- (2009) Xiao-Song Zhong et al. MOLECULAR THERAPY
- The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
- (2008) Stephen Blake et al. CLINICAL IMMUNOLOGY
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
- (2008) M Campoli et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now